Treatment: Avelumab as provided by treating physician. https://clinicaltrials.gov/ct2/show/NCT04822350 Sponsor: Pfizer Preliminary results were presented at the 2022 ESMO Congress for 267 patients who had begun avelumab maintenance at least 6 months before data cutoff.

This change meets the ASCO and ESMO threshold for a clinically meaningful benefit, suggesting that the adoption of ICIs has been associated with meaningful benefit for younger patients with NSCLC,” they summarize.

medwireNews : ESMO has developed a Clinical Practice Guideline to aid physicians in managing patients with metastatic non-small-cell lung cancer (NSCLC) carrying driver mutations.

medwireNews : A Clinical Practice Guideline for the management of non-oncogene addicted metastatic non-small-cell lung cancer (NSCLC) has been issued by ESMO.

medwireNews : ESMO has issued a Clinical Practice Guideline for the prevention and treatment of venous thromboembolism (VTE) in people with cancer.

The results are published in The Lancet Oncology following an earlier presentation at the ESMO Congress 2022 in Paris, France, by lead investigator Lucia Del Mastro (IRCCS Ospedale Policlinico San Martino, Genova, Italy).

The “[r]ecommendations are based on available scientific data and [our] collective expert opinion,” note the guideline authors, adding that they followed the ESMO standard operating procedures  for Clinical Practice Guideline development. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group Ann Oncol 2022; doi:10.1016/j.annonc.2022.10.001

The findings were presented in a poster at the ESMO Congress 2022 in Paris, France, by Soumaya Labidi (Jewish General Hospital, Montreal, Quebec, Canada) and colleagues.

ESMO 2022 video He explained that EV monotherapy has previously shown antitumor activity in pretreated patients with advanced disease, while cohort A of EV-103 demonstrated promising efficacy of the combination in untreated cisplatin-ineligible patients.

And they concluded: “These results further support the recommendation of avelumab [first-line] maintenance as standard of care for patients with [locally advanced or metastatic] UC that has not progressed with [first-line] platinum-based chemotherapy.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany ESMO Congress 2022; Paris, France: 9–13 September

He also stressed the need “to invest in biomarker studies of contemporary regimens […] and pivot rapidly to prospective studies that assess these biomarkers,” as well as “to shift towards adding agents with novel [mechanisms of action] that may not yield overlapping toxicities.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Congress 2022; Paris, France: 9–13 September

There was one treatment-related death in the sotorasib arm and two in the docetaxel arm. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Congress 2022; Paris, France: 9–13 September

She concluded: “In my opinion, the high risk associated with four or more involved lymph nodes [means that] all these patients should receive extended adjuvant endocrine therapy.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Congress 2022; Paris, France: 9–13 September

The findings of the RADICALS-HD study were presented by Chris Parker, from The Royal Marsden Hospital – NHS Foundation Trust in Sutton, UK, at the ESMO Congress 2022 in Paris, France.

Popat concluded that he looks forward to additional data on longer term disease-free survival, patterns of relapse over time, outcomes by minimal residual disease, and overall survival. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Congress 2022; Paris, France: 9–13 September

However, she pointed out that the current study has a shorter duration of follow-up, at 5.4–5.6 months versus 13 months, and therefore “we need longer follow-up to confirm activity” and toxicity. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Congress 2022; Paris, France: 9–13 September

ESMO 2022 video: Joaquim Bellmunt outlines an analysis of the JAVELIN Bladder 100 trial hinting at the utility of epigenetic biomarkers in advanced

ESMO 2022 video: Jonathan Rosenberg reports on cohort K of the EV-103 trial evaluating enfortumab vedotin as a first-line option for advanced

Noting the “practice-changing results” of the DESTINY-Breast04 trial of trastuzumab deruxtecan in previously treated patients with HER2-low disease, the majority of whom were HR+, the discussant wondered about the optimal sequencing of the agents. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Congress 2022; Paris, France: 9–13 September